Company profile
CAPRICOR THERAPEUTICS, INC.
NASDAQ:CAPRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Deramiocel | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03406780 | phase2 | completed | 2018-04-04 | 2020-03-10 | Capricor Inc. | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT05126758 | phase3 | active_not_recruiting | 2022-06-22 | 2025-06-18 | Capricor Inc. | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT01458405 | phase1_2 | terminated | 2012-11-13 | 2017-07-03 | Capricor Inc. | Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration |
| NCT02293603 | phase1 | unknown | 2014-11-01 | 2015-05-01 | Capricor Inc. | Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) |
| NCT02485938 | phase2 | completed | 2016-01-07 | 2017-09-14 | Capricor Inc. | HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) |
FDA applications (0)
No records yet.